www.xinhuanet.com
XINHUA online
CHINA VIEW
VIEW CHINA
 Breaking News Another train derails in Japan     Death toll rises to 71 in Japan's train crash     At least 20 injured in train derail in Japan     About 50 feared injured in Japan train crash     PNA names new security apparatuses chiefs    Berlusconi forms Italy's new government     
Home  
China  
World  
Business  
Technology  
Opinion  
Culture/Edu  
Sports  
Entertainment  
Life/Health  
Travel  
Weather  
  About China
  Map
  History
  Constitution
  CPC & Other Parties
  State Organs
  Local Leadership
  White Papers
  Statistics
  Major Projects
  English Websites
  BizChina
- Conferences & Exhibitions
- Investment
- Bidding
- Enterprises
- Policy update
- Technological & Economic Development Zones
Source Manufacturers and Suppliers from China and around the world
   News Photos Voice People BizChina Feature About us   
Aspen to produce new AIDS drugs in Africa
www.chinaview.cn 2005-04-26 16:25:31

    JOHANNESBURG, April 26 (Xinhuanet) -- Africa's biggest generic drug maker, Aspen Pharmacare, has entered into a nonexclusive agreement with US drug maker Gilead Sciences to manufacture its patented AIDS drugs.

    Local daily Business Day reported on Tuesday that under the terms of the deal, which would be finalized in September, Aspen would have the distribution rights for the Truvada and Viread drugs in Africa.

    The deal is good news for Aspen as it broadens its portfolio of antiretroviral AIDS drugs, which already includes generic copies of patented drugs made by Glaxo SmithKline, Boehringer Ingelheim and Bristol-Meyers Squibb.

    But AIDS activists questioned whether the deal would bring prices down for patients. AIDS law project attorney Jonathan Berger said the deal meant Aspen would take over part of Gilead's not-for-profit market, rather than becoming a competitor offering cheaper, generic versions of the drugs.

    Aspen's head of strategic trade, Stavros Nicolau, said Gilead would provide Aspen with the ingredients and technology to make the drugs, and Aspen would seek licensing approval in African countries where they were not registered. Aspen had lodged an application to register Viread with the Medicines Control Council and planned to follow suit with Truvada shortly.

    Nicolau declined to comment on projected sales volumes, but said the African market had strong potential as only about 7-8 percent of patients who needed AIDS drugs had access to them.

    Viread and Truvada are new-generation antiretrovirals that are increasingly prescribed in the United States and Europe for strains of HIV that are resistant to other drugs. They had fewer side effects and were taken only once a day, said Nicolau. Enditem

    

  Related Story
Stunning backs
Romania, Bulgaria sign "historic" EU entry pact
"Dragon Squad" to premiere in October
- China: EU textile move could harm trade ties
- China's anti-hacking alliance regrouped
- 73 dead, over 400 injured in Japan's train crash
- EU, US recognize Ecuador's new govt
- US prison population reaches new high
- Taiwan PFP chief to begin mainland trip on May 5
- 16 arrested for illegal actions in anti-Japan rally in Shanghai
- Putin: Soviet collapse "catastrophe of century"
- Putin: Soviet collapse "catastrophe of century"
- Iraqi parties fail to agree on govt lineup
- Czech names new prime minister
- Ecuador's new president promises political reforms
- EU, US recognize Ecuador's new government
- World leaders urged to decide on UN reform
- Russia may start pulling out from Georgia
- Iran's Rafsanjani set to run for presidency
Copyright ©2003 Xinhua News Agency. All rights reserved.
Reproduction in whole or in part without permission is prohibited.